Back to Markets
Stocks● Neutral
India's weight-loss drug boom raises questions over healthcare priorities
India's generic anti-obesity drug market surged tenfold in a year, driven by diabetes patients and cosmetic users. Regulators are cracking down on ads and sales, threatening pharma companies' investments in GLP-1 generics.
Continue with
Over the past year, the Indian market for low-cost generic anti-obesity drugs expanded tenfold. Most buyers are diabetes patients managing their weight. A separate wave of consumers – people without a medical need – is driving sales for cosmetic weight loss. The imbalance has drawn the attention of drug regulators.
The Advertising Standards Council in India recently issued warnings about misleading claims in weight-loss drug advertisements. State drug authorities are considering restrictions on over-the-counter sales. A regulatory clampdown on access would test the market's growth trajectory.
The drugs belong to the GLP-1 receptor agonist class, originally developed for type 2 diabetes. They suppress appetite effectively but carry side effects: nausea, vomiting, and diarrhea. Weight regain after stopping the medication is common. The long-term safety profile in otherwise healthy users remains under study.